位置:首页 > 产品库 > KY-02327 acetate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
KY-02327 acetate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
KY-02327 acetate图片
规格:98%
分子量:433.5
包装与价格:
包装价格(元)
5mg询价
10mg询价

KY-02327 acetate 是代谢稳定的 KY-02061 类似物,是一种有效的 Dishevelled (Dvl)-CXXC5 相互作用抑制剂。KY-02327 acetate 对 Wnt/β-catenin 途径具有激活作用,从而促进成骨细胞分化。
货号:ajcx39422
CAS:N/A
分子式:C22H31N3O6
分子量:433.5
溶解度:DMSO : 50 mg/mL (115.34 mM; ultrasonic and warming and heat to 60°C)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation[1].

KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) acetate increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner[1].KY-02327 (1-10 μM) acetate increases the mRNA levels of osteoblast differentiation markers collagen 1a (Col1a) and osteocalcin (OCN)[1].

KY-02327 (20 mg/kg; p.o.; 5 sequential days per week for 4 weeks) acetate successfully rescues bone loss in the ovariectomized (OVX) mouse model[1].

[1]. Kim HY, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016;8(4):375-387.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024